RRML - The neuroendocrine markers assay and the glycemia profile in patients with neuroendocrine tumors under octreotide therapy: a 2 years study
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2020): 1.027

Rejection rate (2020): 75%

Română English


Clarivate analytics (ISI) Impact factor


Advanced search


Top 10 downloaded articles
- September 2021 -
 
Insights into Innate Immune Re... 22
Correction factor between two ... 13
The effects of microwave radia... 10
The Expression of miR-155-5p a... 9
Genetic Diagnostic Approaches ... 7
Romanian Review of Laboratory ... 6
Essentials in the diagnosis of... 6
Atellica CH 930 chemistry anal... 6
Molecular diagnostic of Ureapl... 5
Prognostic value of serum lact... 5

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 22(3)/2014 DOI:10.2478/rrlm-2014-0030
XML
TXT

The neuroendocrine markers assay and the glycemia profile in patients with neuroendocrine tumors under octreotide therapy: a 2 years study

Cătălina Poiană, Diana Păun, Mara Carsote


Abstract:

The neuroendocrine tumors (NETs) are more frequent during the last decades. One of the major tools to evaluate this type of pathology is the neuroendocrine markers as chromogranin A (ELISA), serotonin (ELISA), urinary 5-hydroxy indolacetic acid (HPLC), and neuron specific enolase (IRMA). They change related to the disease progression, regardless therapy. Some of the drugs that are used for NETS as somatostatin analogs (for example octreotide) might interfere with glucose metabolism. Objectives. We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile. Material and Methods. All the patients had at least one assay per year. Results. 9 patients were included (5 women and 4 men), with a mean age of 57.33 years. They were treated before the study with octreotide for 18 +/- 14.69 months. The dose of octreotide varied from 20 to 50 mg, monthly. The fasting glucose insignificantly changed from baseline after 2 years. No new case of diabetes was registered. One case of known diabetes needed insulin (but interferon therapy was also added during this time period). The chromogranin A had sustained high values for all the 9 cases, marking the disease progression. The neuron specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms. Conclusion. The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not correlated.

Keywords: chromogranin A, neuroendocrine tumor, serotonin

Received: 24.8.2013
Accepted: 5.8.2014
Published: 1.9.2014

 
  PDF Download full text PDF
(317 KB)
     
 
How to cite
Poiană C, Păun D, Carsote M. The neuroendocrine markers assay and the glycemia profile in patients with neuroendocrine tumors under octreotide therapy: a 2 years study. Rev Romana Med Lab. 2014;22(3):369-75. DOI:10.2478/rrlm-2014-0030